
    
      This is a single-centered, non-randomized and open-labeled Clinical Pharmacokinetics Study of
      Nimotuzumab in patients with solid tumors. The test includes 3 dose groups, namely Single
      dose group, Multiple single-week dose group and Multiple bi week dose group, to evaluate the
      pharmacokinetic characteristics of Nimotuzumab combined with Irinotecan in patients with
      solid tumors.
    
  